BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) insider Henry J. Fuchs sold 15,000 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $89.23, for a total transaction of $1,338,450.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Shares of BioMarin Pharmaceutical Inc. (BMRN) traded up $0.07 during mid-day trading on Friday, reaching $90.05. 325,878 shares of the company’s stock traded hands, compared to its average volume of 1,339,950. The company has a quick ratio of 3.81, a current ratio of 4.91 and a debt-to-equity ratio of 0.41. The firm has a market cap of $15,810.00, a P/E ratio of -108.49 and a beta of 1.81. BioMarin Pharmaceutical Inc. has a 52-week low of $80.10 and a 52-week high of $100.51.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.06. The firm had revenue of $334.18 million for the quarter, compared to the consensus estimate of $347.38 million. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The business’s quarterly revenue was up 19.4% on a year-over-year basis. During the same period last year, the company posted $0.02 EPS. sell-side analysts forecast that BioMarin Pharmaceutical Inc. will post -0.64 earnings per share for the current year.
Institutional investors and hedge funds have recently modified their holdings of the company. Toronto Dominion Bank grew its stake in shares of BioMarin Pharmaceutical by 12.9% during the 2nd quarter. Toronto Dominion Bank now owns 2,124 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 243 shares in the last quarter. Commerce Bank bought a new position in shares of BioMarin Pharmaceutical in the third quarter valued at $209,000. Cambridge Investment Research Advisors Inc. bought a new position in shares of BioMarin Pharmaceutical in the second quarter valued at $213,000. Teacher Retirement System of Texas bought a new position in shares of BioMarin Pharmaceutical in the third quarter valued at $220,000. Finally, First Republic Investment Management Inc. bought a new position in shares of BioMarin Pharmaceutical in the third quarter valued at $220,000. 99.02% of the stock is owned by institutional investors.
A number of brokerages have recently issued reports on BMRN. Wedbush restated an “outperform” rating and issued a $110.00 price objective on shares of BioMarin Pharmaceutical in a research note on Friday, December 22nd. BidaskClub upgraded shares of BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 16th. Goldman Sachs Group upgraded shares of BioMarin Pharmaceutical from a “buy” rating to a “conviction-buy” rating in a research note on Friday, December 15th. SunTrust Banks increased their price objective on shares of BioMarin Pharmaceutical to $130.00 and gave the company a “buy” rating in a research note on Monday, December 11th. Finally, JPMorgan Chase & Co. set a $131.00 price objective on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research note on Monday, November 27th. Three analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. BioMarin Pharmaceutical currently has a consensus rating of “Buy” and a consensus price target of $112.32.
ILLEGAL ACTIVITY WARNING: “Insider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Insider Sells 15,000 Shares of Stock” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://ledgergazette.com/2018/01/12/biomarin-pharmaceutical-inc-bmrn-insider-henry-j-fuchs-sells-15000-shares.html.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.